# Rosalie Markezich

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/rosalie-markezich
Canonical HTML page: https://getbiobrief.com/entity/rosalie-markezich

## Timeline

- **2026-09-09**: 5th Circuit hears mifepristone arguments — Louisiana AG Liz Murrill and Rosalie Markezich argue for tighter prescribing rules before a three-judge panel in New Orleans.
- **2025**: Louisiana pill access estimated at 770–900 monthly — A Society for Family Planning survey estimates that 770–900 Louisiana women per month obtained abortion pills from out-of-state providers under shield laws.
- **2022-06-24**: Supreme Court allows states to decide abortion issue — The Dobbs decision clears the path for state abortion bans and sets up the current legal battles over cross-border medication abortion.

## Recent coverage (2 stories)

### 3 in 5 abortions use mifepristone as 5th Circuit weighs limits
2026-09-09 21:58:20 · Sentiment: Negative · Impact: 7/10 · Sources: 2

For biopharma, the dispute over mifepristone prescribing rules is a test of FDA regulatory authority over an approved drug's risk evaluation and mitigation strategy. The case may influence how drug safety restrictions are litigated and how federal preemption applies to medication abortion.
Full story: https://getbiobrief.com/story/mifepristone-rems-fda-5th-circuit-biopharma

### Mifepristone in 60% of U.S. abortions faces FDA rule fight in 5th Circuit
2026-09-09 12:39:59 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

The biopharmaceutical sector is watching the 5th Circuit review of mifepristone's FDA prescribing rules. At least 60% of U.S. abortions use the two-drug regimen, making the drug's distribution and label conditions a high-stakes regulatory precedent.
Full story: https://getbiobrief.com/story/mifepristone-fda-rule-review-biopharma

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.